The round was led by Nextech Invest, BMS, and other undisclosed investors along with all existing investors incl. Atlas Venture, F-Prime Capital, and Eight Roads Ventures
The fund will be utilized to develop the ongoing dose escalation P-I study evaluating the safety tolerability, and efficacy of KTX-1001 + SoC and the expansion of KTX-1001 into other hematological and solid tumor indications
KTX-1001 is an orally administered small molecules, H3K36 methyltransferase MMSET inhibitor being developed to treat r/r multiple myeloma patients with the genetic translocation t(4;14)
Ref: PRNewswire | Image: K36 Therapeutics
Related News:- Janssen and Legend Biotech Report the sBLA Submission of Carvykti (ciltacabtagene autoleucel) to the US FDA for Relapsed or Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
